| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LAQ824 | GDSC1000 | pan-cancer | AAC | -0.0069 | 0.8 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | CID-5951923 | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.8 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.8 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.8 |
| mRNA | KPT185 | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.8 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.8 |